Home
Search
Study Topics
Glossary
|
|
|
|
|
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date † | February 18, 2007 | ||||
Last Updated Date | August 24, 2008 | ||||
Start Date † | May 2007 | ||||
Current Primary Outcome Measures † |
Time to disease progression [ Time Frame: The follow up period will be five years after the last dose has been administered. ] [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures † | Same as current | ||||
Change History | Complete list of historical versions of study NCT00438100 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures † |
|
||||
Original Secondary Outcome Measures † |
|
||||
Descriptive Information | |||||
Brief Title † | Xeloda vs. TS-1 as First-Line Treatment in Unresectable or Recurrent Breast Cancer | ||||
Official Title † | Randomized Control Study of Xeloda Alone vs. TS-1 Alone as First-Line Treatment in Unresectable or Recurrent Breast Cancer Patients | ||||
Brief Summary | To investigate and compare the efficacy and safety of TS-1 vs. Xeloda as primary chemotherapy in patients with inoperable or recurrent breast cancer. |
||||
Detailed Description | The incidence of breast cancer is increasing in Japan: 33,676 women were diagnosed with breast cancer in 2001, making it the leading cause of cancer among women since 1995. Statistical database in Exel format/outline of health welfare statistics from the Ministry of Labor, Health, and Welfare show that the number of deaths from breast cancer was 9,806 in 2003. Because the ten-year survival rate is about ninety percent in Stages 0 and I breast cancer patients, detection and treatment at an earlier stage can lead to higher survival rates. However, the recurrence rate increases as the disease progresses. In addition, about thirty percent of all breast cancer patients are believed to have recurrent disease. Thus, developing treatments against recurrence may be an important task. The Guideline for Breast Cancer Treatment, 2004 version, recommends chemotherapy, including anthracyclines or taxanes as a first-line chemotherapy for metastatic or recurrent (grade B recommendation) breast cancer. In a second-line therapy recommended for metastatic or recurrent diseases, the Guideline reports that a combination of capecitabine, a 5Fu derivative (an oral chemotherapy of pyrimidine fluorides approved in 2003) with docetaxel is superior to docetaxel alone for improving survival. This regimen is recommended for patients with cardiac malfunction who cannot be treated with anthracyclines (grade B recommendation). However, data are lacking to support capecitabine as a standard regimen as a second-line therapy; its efficacy needs verification and further study. Accordingly, this study is designed to investigate the efficacy and safety of TS-1 alone, an oral pyrimidine fluoride, to which an indication of "inoperable or recurrent breast cancer" was added, as a first-line therapy in patients with inoperable or recurrent breast cancer by comparing it with Xeloda (capecitabine) alone, which is already approved of the same indication. |
||||
Study Phase | Phase II | ||||
Study Type † | Interventional | ||||
Study Design † | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study | ||||
Condition † | Breast Neoplasms | ||||
Intervention † |
|
||||
Study Arms / Comparison Groups |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status † | Recruiting | ||||
Enrollment † | 220 | ||||
Estimated Completion Date | May 2024 | ||||
Estimated Primary Completion Date | May 2022 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Female | ||||
Ages | 25 Years to 74 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts †† |
|
||||
Location Countries † | Japan | ||||
Expanded Access Status | |||||
Administrative Information | |||||
NCT ID † | NCT00438100 | ||||
Responsible Party | Japan Breast Cancer Research Network, Japan Breast Cancer Research Network | ||||
Secondary IDs †† | UMIN000000609 | ||||
Study Sponsor † | Japan Breast Cancer Research Network | ||||
Collaborators †† | |||||
Investigators † |
|
||||
Information Provided By | Japan Breast Cancer Research Network | ||||
Verification Date | August 2008 | ||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |